Personalized sleep therapies powered by non-invasive monitoring

Team

Michal Maslik

Co-Founder

Fares Siddiqui

CEO and Co-founder

Zhiguang Mu

Co-Founder

Hanyi Hu

Co-Founder

Circadia

Company details

Circadia enables the early detection of respiratory complications, the third leading cause of death, to save patient lives. The company provides an inexpensive, medical-grade, frictionless solution to clinicians in order to help improve patient outcomes, reduce provider workload and reduce the cost of care. Circadia’s C100 Contactless Respiratory Monitoring System conveniently monitors patients with acute respiratory illnesses both in-facility and remotely at home. During the pandemic, Circadia is delivering 2,000 C100 devices to health care facilities to minimize health worker contact and exposure to COVID-19, and is on track to tripling its manufacturing capacity. This follows the FDA’s latest guidance to expand the availability and capability of non-invasive remote respiratory monitoring devices. The company has started deploying its AI-powered C100 with a large hospital in Los Angeles and is in ongoing discussions with global governments and health systems. Read more here.

Get In Touch with Circadia

Please tell us a little bit about yourself and why you'd like to get connected. Circadia + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden
Opt-in checkbox


We don’t spam. Our Privacy Policy and Terms of Use apply.
* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More